|
|
|
| Effects of Salkubatrol Valsartan on Cardiac Function and Inflammatory Factors in Patients with Heart Failure Caused by Decreased Ejection Fraction |
| LIU Tong, YAN Yang-jin, SHI Jing-yi, et al |
| Xi'an NO.3 Hospital/The Affiliated Hospital of Northwest University,Xi'an 710018,Shaanxi |
|
|
|
|
Abstract 【Objective】To investigate the effect of salkubatrol valsartan (S/V) on heart failure with reduced ejection fraction. 【Methods】A total of 104 patients with HFREF was randomly divided into observation group and control group, with 52 cases in each group. The control group was given routine anti heart failure treatment, and the observation group was given S/V treatment on the basis of the control group. The adverse reactions, clinical efficacy after 3 months of treatment and before and after treatment and the levels of cardiac function parameters in the two groups were compared between the two groups included left atrial diameter (LA), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), blood flow mediated vasodilation (FMD), inflammatory factors [interleukin-6 (IL-6), interleukin-33 (IL-33), and tumor necrosis factor-α(TNF-α)and intercellular adhesion factor-1 (ICAM-1)], and the rehospitalization rates of the two groups were recorded.【Results】The total effective rate in the observation group was 96.15%, higher than 75.00% in the control group, The difference was statistically significant (P<0.05). After treatment, LVEF and FMD in the two groups were higher than those before treatment, LVEDD and LA were lower than those before treatment, and the levels of serum IL-6, IL-33 and ICAM-1 in the observation group were lower than those before treatment (P<0.05) . There was no significant difference between the two groups in the total incidence of adverse reactions during treatment and rehospitalization rate within half a year of follow-up (P>0.05). 【Conclusion】The addition of S/V to HFREF on the basis of routine treatment can significantly improve the clinical efficacy, improve the cardiac function of patients, and reduce inflammatory reaction. It has good safety and is worthy of clinical promotion.
|
|
Received: 08 November 2020
|
|
|
|
|
|
[1] 严峻海.多巴胺联合多巴酚丁胺在小儿肺炎心衰中的应用[J].医学临床研究, 2015, 32(6):1221-1222.
[2] 赵跃华. 沙库巴曲缬沙坦(LCZ696)治疗心力衰竭的研究进展[J].临床心血管病杂志, 2019, 35(6):491-494.
[3] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10):760-789.
[4] PETER K, GHAZAL K, SARMAD S, et al. Entresto, a new panacea for heart failure?[J].Cardiovasc Hematol Agents Med Chem,2018, 16(1):5-11.
[5] 江军.沙库巴曲缬沙坦钠联合芪参益气滴丸治疗慢性心衰的疗效观察[J].微循环学杂志, 2019, 29(1):23-27.
[6] AIMO A, EMDIN M, MAISEL A S. Sacubitril/Valsartan,cardiac fibrosis,and remodeling in heart failure[J].J Am Coll Cardiol,2019, 73(23):3038-3039.
[7] 张皓.沙库巴曲缬沙坦对心力衰竭患者相关炎症因子的影响[J].武警后勤学院学报(医学版), 2020, 29(6):6-9.
[8] FERNÁNDEZ-RUIZ I. Mechanisms of sacubitril-valsartan benefit in HFrEF[J].Nat Rev Cardiol,2019, 16(11):648.
[9] 张相杰, 黄文平, 许有凡. 沙库巴曲缬沙坦和盐酸贝那普利片对心力衰竭患者心室重塑、炎症因子的影响[J].实用医学杂志, 2019, 35(5):795-799.
[10] 潘春奇, 菅颖, 倪斌, 等.沙库巴曲缬沙坦对射血分数降低的缺血性心肌病患者心肌损伤和炎症因子的影响[J].中华全科医学, 2020, 18(11):1848-1850.
|
|
|
|
2021, Vol. 38 
